Torrent Pharmaceuticals, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent Pharma's competitive advantage stems from the world-class manufacturing facilities, advanced R & D capabilities, extensive domestic network and a widespread global presence in many countries.

The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceutical business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with 90 year old Heumann from Pfizer to enter the German market. Later on purchased ANDA of Minocycline from Ranbaxy for the US Market in 2015. In January 2018, Torrent also acquired Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA, which also included a US FDA registered manufacturing facility. Torrent Pharma is committed towards ‘not just healthcare but lifecare’.

Business area of the company

Torrent Pharmaceuticals has established itself as a major player in the Indian Pharma arena. The company has well segregated marketing divisions, strategically structured on specific therapeutic areas and enjoys dominance in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). With Unichem's domestic business acquisition, Torrent has entered the list of top pharma firms in the Indian Pharma Market (IPM) and is ranked No 8 in the IPM.

Torrent Pharmaceuticals Ltd.

Abbott India Ltd.

Zydus Lifesciences Ltd.

Dr. Reddy's Laboratories Ltd.

Alkem Laboratories Ltd.

Lupin Ltd.

Biocon Ltd.

Gland Pharma Ltd.

Aurobindo Pharma Ltd.

Glaxosmithkline Pharmaceuticals Ltd.

Laurus Labs Ltd.

Ipca Laboratories Ltd.

Divi's Laboratories Ltd.

Piramal Enterprises Ltd.

Cipla Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	55,031 Cr	ROE	13.2%
P/E Ratio(TTM)	55.6	EPS(TTM)	23.7
P/B Ratio	8.5	Dividend Yield	1.5%
Industry P/E	64.4	Book Value	191.4
		Face Value	5.0

Fundamentals